Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Fawzi Benzaghou"'
Autor:
S. Hazra, J.D. Gomez Rangel, Edward Gane, S. Qin, S.L. Chan, Philippe Merle, Ivan Borbath, Lorenza Rimassa, Fawzi Benzaghou, A-L Cheng, Ahmed Kaseb, Thomas Yau, Gontran Verset, Robin Katie Kelley, Andrew X. Zhu, V. Breder, J. Fawcett, K. Banerjee, Wattana Sukeepaisarnjaroen
Publikováno v:
Annals of Oncology. 33:114-116
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f9018851d2148d57f49e731f9d7e828
https://doi.org/10.1016/j.annonc.2021.10.008
https://doi.org/10.1016/j.annonc.2021.10.008
Autor:
Neeraj Agarwal, Arun Azad, Joan Carles, Simon Chowdhury, Bradley McGregor, Axel S Merseburger, Stéphane Oudard, Fred Saad, Andrey Soares, Fawzi Benzaghou, Yannick Kerloeguen, Akiko Kimura, Nehal Mohamed, Ashok Panneerselvam, Fong Wang, Sumanta Pal
Publikováno v:
Scientia
Atezolizumab; Cabozantinib; Immune checkpoint inhibitor Atezolizumab; Cabozantinib; Inhibidor del punto de control inmunitario Atezolizumab; Cabozantinib; Inhibidor del punt de control immunitari Cabozantinib inhibits multiple receptor tyrosine kinas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60456af416257c39de02bcfd8a52a2c
https://hdl.handle.net/11351/7985
https://hdl.handle.net/11351/7985
Autor:
Jennifer W. Oliver, S. Hazra, Lorenza Rimassa, Thomas Yau, Fawzi Benzaghou, Robin Kate Kelley, Ann-Lii Cheng
Publikováno v:
Future Oncology. 16:1525-1536
Cabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM (TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and angiogenesis, cabozantinib targets promote an immune-suppressive microen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc6ce68d51e26fc3749902dfcb2b7a14
https://doi.org/10.2217/fon-2020-0283
https://doi.org/10.2217/fon-2020-0283
Autor:
Robin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, Ahmed Kaseb, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau
Publikováno v:
The Lancet. Oncology. 23(8)
Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2403442ee71ca9e75dd337788852d5c
https://pubmed.ncbi.nlm.nih.gov/36174622
https://pubmed.ncbi.nlm.nih.gov/36174622
Autor:
Zev A. Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle De La Fouchardiere, Andrew Peter Dean, Igor Kiss, Woojin Lee, Thorsten Oliver Goetze, Eric Van Cutsem, Andrew Scott Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Richard Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen Mary O'Reilly
Publikováno v:
Journal of Clinical Oncology. 41:LBA661-LBA661
LBA661 Background: Liposomal irinotecan administered with 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for mPDAC following progression with gemcitabine-based therapy. A phase 1/2 study (Wainberg et al. Eur J Cancer 2021;151:1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adedb988a055c95df9b251d7f4a27304
https://doi.org/10.1200/jco.2023.41.4_suppl.lba661
https://doi.org/10.1200/jco.2023.41.4_suppl.lba661
Autor:
Nick Freemantle, Patrick Mollon, Tim Meyer, Ann-Lii Cheng, Anthony B. El-Khoueiry, Robin K. Kelley, Ari D. Baron, Fawzi Benzaghou, Milan Mangeshkar, Ghassan K. Abou-Alfa
Publikováno v:
European journal of cancer (Oxford, England : 1990). 168
The CELESTIAL trial (NCT01908426) demonstrated overall survival benefit for cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (aHCC) who had received prior sorafenib treatment. This analysis of CELESTIAL compared the impa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec1516aac29ca369906265fe56b9036f
https://pubmed.ncbi.nlm.nih.gov/35487183
https://pubmed.ncbi.nlm.nih.gov/35487183
Autor:
Fawzi Benzaghou, Manuela Schmidinger, Douglas O. Clary, Frederic Rolland, Ugo De Giorgi, Toni K. Choueiri, Tibor Csoszi, Nizar M. Tannir, Michael Staehler, Michael Rink, Claudia Caserta, Robert J. Motzer, Margitta Retz, Ignacio Duran, Laurence Albiges, John McCaffrey
METEOR was a phase 3 trial (NCT01865747) of cabozantinib versus everolimus in adults with advanced or metastatic clear cell RCC previously treated with VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs). This post hoc analysis of METEOR compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e56388c171711a7970b26f7aa70a93
Autor:
Douglas O. Clary, J. P. Maroto, Linh Nguyen, Fawzi Benzaghou, Daniel Castellano, Eric Jonasch, Naila Taguieva
Publikováno v:
Cancer treatment reviews. 89
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of patients with advanced renal cell carcinoma (RCC) at a dose of 60 mg/day. As with other TKIs, cabozantinib is associated with high interpatient variability in drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee938082446e851fc9f45f89b45c9b67
https://pubmed.ncbi.nlm.nih.gov/32659623
https://pubmed.ncbi.nlm.nih.gov/32659623
Autor:
E Schott, AD Baron, A-L Cheng, P Mollon, Tim Meyer, S. Hazra, Fawzi Benzaghou, Nick Freemantle, V. Valcheva, Milan Mangeshkar, RK Kelley
Publikováno v:
Zeitschrift für Gastroenterologie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3daae9781f2eebfb2570d7618f27ace9
https://doi.org/10.1055/s-0039-1695310
https://doi.org/10.1055/s-0039-1695310
Autor:
R. Sinha, Anne Borgman, Lorenza Rimassa, Fawzi Benzaghou, Fadi Braiteh, S. Hazra, Robin Katie Kelley, A-L Cheng, Andrew X. Zhu, Z. Kayali
Publikováno v:
Annals of Oncology. 30:iv65-iv66
Background C inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER). C is approved in the United States and Europe for treatment of aHCC after prior S based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93814d029436a0b6326eea8ce05c833b
https://doi.org/10.1093/annonc/mdz155.237
https://doi.org/10.1093/annonc/mdz155.237